Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
La Oficina de Propiedad Intelectual de la Unión Europea cierra la solicitud de ayuda del Fondo para pymes (SME Fund) hasta la siguiente convocatoria en 2026.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
193
resultados
Última actualización
08/12/2025 [06:50:00]
Resultados 50 a 75 de 193
Resumen de: US2025367319A1
This disclosure relates to compositions and methods for treating lung disorders, including, for example, pulmonary fibrosis, and other fibrotic disorders. Thioredoxin domain-containing 5 (TXNDC5) is significantly increased in fibrotic lungs from human PF patients. Therefore, a targeted nanoparticle comprising an inhibitor of TXNDC5 was developed, which may have potential to treat pulmonary fibrosis.
Resumen de: US2025367320A1
The present disclosure relates to RNA particles for delivery of RNA to target tissues after administration, in particular after parenteral administration such as intravenous, intramuscular, subcutaneous or intratumoral administration, and compositions comprising such RNA particles. The RNA particles in one embodiment comprise single-stranded RNA such as mRNA which encodes a peptide or protein of interest, such as a pharmaceutically active peptide or protein. The RNA is taken up by cells of a target tissue and the RNA is translated into the encoded peptide or protein, which may exhibit its physiological activity.
Resumen de: US2025367300A1
A self-assembled nanomaterial includes a Janus base nanotube and a biologically active molecule covalently or non-covalently adhered thereto, wherein the Janus base nanotube includes at least one compound represented by disclosed Formulas I, II, III, IV. V. VI, VII, VIII, or IX, or a pharmaceutically acceptable salt thereof.
Resumen de: US2025367274A1
The present application is directed, in general, to tolerizing immune mediated particles comprising gene therapy vector antigens for use in combination with gene therapy regimens in order to reduce immunogenicity to the gene therapy vector antigens and/or transgene protein products expressed by the vectors.
Resumen de: US2025367275A1
The present disclosure provides methods for treating an individual with pancreatic cancer with an individualized cancer vaccine and a PD-1 axis antagonist.
Resumen de: US2025367133A1
The disclosure relates to block copolymer nanoparticles for therapeutic delivery of nucleotides, and methods therefor. More particularly, the invention relates to polymer nanoparticles, such as reversible addition-fragmentation chain transfer (RAFT) polymer compositions, for delivering miRNAs.
Resumen de: US2025367130A1
A composition that includes agent-loaded metal-organic framework nanoparticles dispersed within a thermoresponsive hydrogel, wherein the agent is an agent for treating an ocular condition and the composition is configured for sustained topical ocular release.
Resumen de: US2025367322A1
The disclosure provides nucleic acid-containing lipid nanoparticle (LNP) compositions and methods relating to the delivery of TnpB nucleobase editing systems comprising TnpB polypeptides, engineered TnpB ncRNAs, and optionally one or more additional accessory functionalities (e.g., a deaminase, reverse transcriptase, recombinase, nuclease, a donor template, or combinations thereof) for use in applications such as precision gene editing.
Resumen de: US2025367132A1
Solid lipid nanoparticles (SLNs) for delivery of bioactive compounds are disclosed. The SLNs comprise a lipid matrix and surfactant layer encapsulating at least one bioactive compound selected from vitamins, minerals, enzymes, algae-derived bioactives, proteins, peptides, amino acids, antioxidants, small synthetic molecules, plant-derived volatile compounds, or botanical extracts. The SLNs exhibit submicron particle size, low polydispersity, and sufficient surface charge to ensure colloidal stability and efficient delivery. In one embodiment, algae-based bioactives, such as phycocyanin or fucoxanthin, are encapsulated using only natural and sustainable lipids and surfactants to improve bioavailability and support environmentally friendly formulations. The SLNs may be formulated for oral, topical, transdermal, injectable, ophthalmic, mucosal, textile, veterinary, or agricultural administration. Applications include human and animal health, functional foods, skincare, nutrient supplementation, and crop treatment. The disclosed SLNs offer a biocompatible and scalable delivery system that protects sensitive compounds, enables sustained release, and enhances absorption across diverse industries.
Resumen de: US2025367129A1
Compounds are provided having the following structure: (I) or a pharmaceutically acceptable salt, N-oxide, tautomer or stereoisomer thereof, wherein R1, G1, W and m, n, o and p are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a nucleic acid, compositions comprising the compounds and methods for their use and preparation are also provided.
Resumen de: US2025367128A1
Described are biodegradable lipid nanoparticles (LNPs) comprising biodegradable lipidoids and compositions thereof. In various embodiments, the LNP selectively targets a liver cell. In other aspects, the present invention relates to methods for in vivo delivery of therapeutic nucleic acids to the liver to prevent or treat diseases or disorders using the LNP compositions of the invention.
Resumen de: US2025367118A1
Disclosed are nanoparticles and nanogel drug compositions and the use thereof for treating age-related macular degeneration.
Resumen de: US2025367110A1
Compositions for treating ocular disease are disclosed herein. In some embodiments, the composition comprises a dynamic hydrogel comprising a polymer and a plurality of nanoparticles, wherein the polymer is non-covalently crosslinked with the plurality of nanoparticles. The dynamic hydrogel can also comprise an ocular therapeutic encapsulated by the dynamic hydrogel.
Resumen de: US2025367135A1
The present invention relates to a dendritic cell-mimicked nanostructure and a fabrication method therefor and, more specifically, to a nanostructure in which a shell including a cell membrane of dendritic cell-derived lipid molecules is introduced to a nanoparticle core in order to take advantage of the surface antigen-presenting ability of dendritic cells and which enables targeting without disappearance in vivo, thereby providing an effect of inducing an effective immune response.
Resumen de: US2025367131A1
The invention encompasses novel ionizable lipids compounds and their use in lipid nanoparticles delivery systems that are useful in the delivery of nucleic acids to a mammalian subject that can be included for use, for example, as cancer vaccines, gene editing therapeutics, delivery of nucleic acid (e.g., mRNA) encoding antibodies, vaccines for infectious disease, and protein replacement therapeutics. Additionally, the invention encompasses compositions and therapeutics comprising the ionzable lipids in the lipid nanoparticles and the use of the composition and therapeutics for the preparation of a pharmaceutical composition, especially a vaccine, (e.g., for use in the prophylaxis or treatment of infectious diseases, tumor or cancer diseases, rare diseases, allergies, or autoimmune diseases). The invention encompasses methods of treatment or prophylaxis of the aforementioned diseases.
Resumen de: US2025367134A1
The technology includes selective modulation of only a peripheral CB1R by using a CB1R antagonist contained in a peripherally restricted delivery system.
Resumen de: EP4656213A1
The present invention relates to a pharmaceutical, dental and/or cosmetic composition comprising purified and/or isolated matrix derivative (EMD) proteins and a suitable pharmaceutical carrier, characterized in that the purified and/or isolated enamel matrix derivative (EMD) proteins comprised in said composition have a predominant MW of between 10-13kDa and an aggregation particle size of between 20-200 nm at Room Temperature (RT) and a pH of between 6.0-7.5.Said pharmaceutical, dental and/or cosmetic composition is disclosed for use in healing, restoration, enhancement and/or promotion of soft tissue in the oral cavity and/or craniomaxillofacial complex (CMF), in particular for use in treating patients suffering from a gingival deficiency and/or disorder. Preferably, the composition of the invention is administered via injection into the soft tissue in the oral cavity and/or the craniomaxillofacial complex (CMF) of the patient.
Resumen de: AU2024212425A1
Disclosed herein are modified lipid compositions comprising (a) a structural component comprising one or more lipids selected from the group consisting of soy-derived lipids, cardiolipin, sphingolipid, ceramide, glucosyl ceramide, lactosyl ceramide, galactosyl cholesterol, glucosyl cholesterol; and modified by (b) an ionizable lipid. The disclosure also includes a method for making a modified lipid composition, comprising reconstructing (a) a structural component comprising one or more lipids selected from the group consisting of soy-derived lipids, cardiolipin, sphingolipid, ceramide, glucosyl ceramide, lactosyl ceramide, galactosyl cholesterol, and/or glucosyl cholesterol in the presence of (b) an ionizable lipid, to produce the modified lipid composition, and loading into the modified lipid composition with one or more heterologous functional agents.
Resumen de: MX2025005655A
The present invention refers to novel polyoxyalkylene based compounds and their manufacturing method as well as compositions comprising at least one novel polyoxyalkylene based compound and at least one active agent. Furthermore, the present invention refers to the manufacture of the compositions of the present invention as well as their use for the treatment of an illness in mammals or humans.
Resumen de: CA3272967A1
It provides a method for treating and/or preventing edematous fibrosclerotic panniculopathy (EFP) in a subject in need thereof. The method includes administering to the subject an effective amount of a pharmaceutical composition. The pharmaceutical composition includes a plurality of amphiphilic nanoparticles having one or more active ingredients encapsulated therein. Each of the amphiphilic nanoparticles is formed by a non-ionic surfactant, a polymeric carrier, or a lipid carrier. The hydrophilic-lipophilic balance (HLB) value of the non-ionic surfactant is greater than 9. The pharmaceutical composition is administered via a parenteral route by an injection, a microneedle, or an implant, or via topical administration or transdermal administration.
Resumen de: MX2025005575A
The present invention refers to novel polyoxyalkylene based compounds and their manufacturing method as well as compositions comprising at least one novel polyoxyalkylene based compound and at least one active agent. Furthermore, the present invention refers to the manufacture of the compositions of the present invention as well as their use for the treatment of an illness in mammals or humans.
Resumen de: US2025367129A1
Compounds are provided having the following structure: (I) or a pharmaceutically acceptable salt, N-oxide, tautomer or stereoisomer thereof, wherein R1, G1, W and m, n, o and p are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a nucleic acid, compositions comprising the compounds and methods for their use and preparation are also provided.
Resumen de: MX2025005144A
The present invention relates to novel polypeptides, which are derived from transforming growth factor beta 1 (TGFβ1; TGFb-1) as well as polynucleotides encoding such polypeptides and compositions comprising such peptides. The present invention is further concerned with ways to increase the selectivity of the immune response to TGFb-1. The invention also concerns uses, and methods of using, said polypeptides, polynucleotides, and compositions.
Resumen de: CN120019041A
The present invention relates to a lipid having an amide functional group and an ester functional group and a method for preparing the same, and more particularly, to an ionized lipid which forms a complex with an anionic drug, and which can be used for drug delivery due to a specific structure having an amide functional group and an ester functional group, and a method for preparing the same.
Nº publicación: EP4656180A1 03/12/2025
Solicitante:
CANTREAT AG [CH]
Cantreat AG
Resumen de: EP4656180A1
Nanoteilchen (1) zur Verabreichung zumindest eines Wirkstoffs (4), umfassend einen magnetisierbaren Kern (2), wobei der Kern (2) eine Ummantelung (3) aus einem Polyphosphat aufweist, wobei die Ummantelung (3) den Kern (2) vollständig umschließt, dadurch gekennzeichnet, dass die Ummantelung (3) mit einem Wirkstoff (4) versetzt ist.
BOPI
Sede Electrónica
